Chinese researchers:
GZNL-P36 is a promising drug candidate for COVID-19 targeting a conserved viral enzyme, showing broad antiviral and anti-inflammatory effects.
Mouse trials: it reduces viral load, inflammation, and lung damage
Researchers at The University of Hong Kong developed TMP1, an oral drug blocking coronavirus entry and replication.
Tested in mice and hamsters, it was effective against SARS-CoV-2 variants and drug-resistant strains.
My note: Would like to see study on this drug with endpoints like time to recovery, severity of symptoms, long-term follow-up for post-acute symptoms. Not holding my breath. This is, after all, Giliad, the maker of remdesivir. Still, potential early treatment option here:
465 adults received either obeldesivir or a placebo for 5 days. The results showed that those on obeldesivir had a 0% hospitalization rate and lower mortality compared to 0.5% in the placebo group.
Patients taking obeldesivir also experienced quicker symptom relief and greater reductions in the virus levels. Overall, the drug was found to be generally safe and well-tolerated.
Anti-Viral Impact of Metformin “When AMPK was activated in Calu3 and Caco2 cell lines using metformin, there was a remarkable suppression of SARS-CoV-2 infectious titers, with up to 99% reduction observed in infected cells.”
Metformin suppresses SARS-CoV-2 in cell culture
Next generation medicines in fight against Covid:
Focusing specifically on the receptor-binding domain (RBD) rather than the entire SARS-CoV-2 spike protein provides enhanced, long-lasting protection against viral mutations
“INCLUSION OF MEGLUMINE ACRIDONE ACETATE (MA): CYCLOFERON
